Each filer's latest filing for 022307102 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Foresite Capital Fund VI LP
13D/A
|
12.7% |
4/3/2026
Event 4/1/2026
|
||
| Foresite Capital Fund VI LP | 3.4% | |||
| Foresite Capital Management VI, LLC | 3.4% | |||
| Foresite Capital Fund V, L.P. | 4.6% | |||
| Labs Co-Invest V, LLC | 0.2% | |||
| Foresite Capital Management V, LLC | 4.8% | |||
| Foresite Capital Opportunity Fund V, L.P. | 2.4% | |||
| Foresite Capital Opportunity Management V, LLC | 2.4% | |||
| Foresite Labs Fund I, L.P. | 1.6% | |||
| Foresite Labs Management I, LLC | 1.6% | |||
| Foresite Labs Affiliates 2021, LLC | 0% | |||
| Foresite Labs, LLC | 0% | |||
| James B. Tananbaum | 12.7% | |||
|
AyurMaya Capital Management Company, LP
13D/A
|
12.3% |
7/2/2026
Event 5/14/2026
|
||
| AyurMaya Capital Management Company, LP | 12.3% | |||
| David E. Goel | 12.3% | |||
|
Deep Track Capital, LP
13G
|
6.0% |
4/7/2026
Event 3/30/2026
|
||
| Deep Track Capital, LP | 6.0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 6.0% | |||
| David Kroin | 6.0% | |||
| BlackRock, Inc. 13G | 5.7% |
7/27/2026
Event 6/30/2026
|
||
|
Samsara BioCapital, L.P.
13D/A
|
5.4% |
1/13/2026
Event 1/9/2026
|
||
| Samsara BioCapital, L.P. | 3.8% | |||
| Samsara BioCapital GP, LLC | 3.8% | |||
| Samsara Opportunity Fund, L.P. | 1.6% | |||
| Samsara Opportunity Fund GP, LLC | 1.6% | |||
| Srinivas Akkaraju | 5.4% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
venBio Global Strategic Fund IV, L.P.
13G/A
|
4.8% |
11/17/2025
Event 6/30/2025
|
||
| venBio Global Strategic Fund IV, L.P. | 4.8% | |||
| venBio Global Strategic GP IV, LLC | 4.8% | |||
| Adelman Robert J | 4.8% | |||
| Goodman Corey S | 4.8% | |||
|
FMR LLC
13G/A
|
0% |
11/5/2026
Event 9/30/2026
|
||
| FMR LLC | 0% | |||
| Abigail P. Johnson | 0% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 209 | 112 M | $829M |
| 2026 Q2 | 203 | 118 M | $3.32B |
| 2026 Q1 | 200 | 115 M | $2.53B |
| 2025 Q4 | 136 | 79.1 M | $771M |
| 2025 Q3 | 130 | 62.9 M | $251M |
| 2025 Q2 | 114 | 78.3 M | $235M |
| 2025 Q1 | 73 | 40.2 M | $247M |
| 2024 Q4 | 65 | 40.3 M | $316M |
| 2024 Q3 | 53 | 35.2 M | $376M |
| 2024 Q2 | 30 | 28.6 M | $380M |